Eli Lilly Advances Weight-Loss Pipeline with Retatrutide Results and Orforglipron Stockpiling
Dec 12, 2025
Eli Lilly reported positive Phase 3 results for retatrutide showing up to 71.2 lbs average weight loss, while stockpiling $1.5 billion of oral drug orforglipron ahead of anticipated FDA approval in April 2026.